Psychological factors and stress in inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 3, 2013, Pages 225-238

  Triantafillidis, John K ^a   Merikas, Emmanuel ^a   Gikas, Aristofanis ^a  

^a Saint Panteleimon General Hospital   (Greece)

Author keywords

Crohn's disease; etiology; inflammatory bowel disease; psychological factors; stress; ulcerative colitis

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABIDIOL; CANNABIS; CORTICOSTEROID; LITHIUM; PSYCHOTROPIC AGENT;

ANXIETY; COGNITIVE THERAPY; COPING BEHAVIOR; CROHN DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; EGO; EMOTION; ENTERITIS; HUMAN; LIFE EVENT; MENTAL STRESS; MOOD DISORDER; MUCOSA INFLAMMATION; NONHUMAN; PROBLEM SOLVING; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SLEEP DISORDER; TRAINING; ULCERATIVE COLITIS;

DEPRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; PSYCHOLOGY; PSYCHOTHERAPY; QUALITY OF LIFE; RISK FACTORS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84874632954     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.4     Document Type: Review

References (114)

1. Schoultz M. The role of psychological factors in inflammatory bowel disease. Br. J. Community Nurs. 17(8), 370-374 (2012).
2. Reber SO. Stress and animal models of inflammatory bowel disease-an update on the role of the hypothalamo-pituitary-adrenal axis. Psychoneuroendocrinology 37(1), 1-19 (2012).
3. Cantor DS. Crohn's disease and psychiatric illness. Gastroenterology 87(2), 478-479 (1984).
4. North CS, Clouse RE, Spitznagel EL, Alpers DH. The relation of ulcerative colitis to psychiatric factors: a review of findings and methods. Am. J. Psychiatry 147(8), 974-981 (1990).
5. Drossman DA. Psychosocial factors in inflammatory bowel disease. In: Inflammatory Bowel Disease. Kirsner JB, Shorter RG (Eds). Williams & Wilkins, MD, USA (1995).
6. Nahon S, Lahmek P, Durance C et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm. Bowel Dis. 18(11), 2086-2091 (2012).
7. McMahon AW, Schmitt P, Patterson JF, Rothman E. Personality differences between inflammatory bowel disease patients and their healthy siblings. Psychosom. Med. 35(2), 91-103 (1973).
8. Robertson DA, Ray J, Diamond I, Edwards JG. Personality profile and affective state of patients with inflammatory bowel disease. Gut 30(5), 623-626 (1989).
9. Gazzard BG, Price HL, Libby GW, Dawson AM. The social toll of Crohn's disease. Br. Med. J. 2(6145), 1117-1119 (1978).
10. Barrett SM, Standen PJ, Lee AS, Hawkey CJ, Logan RF. Personality, smoking and inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 8(7), 651-655 (1996).
11. North CS, Alpers DH, Helzer JE, Spitznagel EL, Clouse RE. Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann. Intern. Med. 114(5), 381-386 (1991).
12. Kurina LM, Goldacre MJ, Yeates D, Gill LE. Depression and anxiety in people with inflammatory bowel disease. J. Epidemiol. Community Health 55(10), 716-720 (2001).
13. Bennebroek Evertsz' F, Thijssens NA, Stokkers PC et al. Do inflammatory bowel disease patients with anxiety and depressive symptoms receive the care they need? J. Crohns. Colitis 6(1), 68-76 (2012).
14. Häuser W, Janke KH, Klump B, Hinz A. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm. Bowel Dis. 17(2), 621-632 (2011).
15. Filipovic BR, Filipovic BF, Kerkez M, Milinic N, Randelovic T. Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon. World J. Gastroenterol. 13(3), 438-443 (2007).
16. Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P. Psychological issues in inflammatory bowel disease: an overview. Gastroenterol. Res. Pract. 2012, 106502 (2012).
17. Walker JR, Ediger JP, Graff LA et al. The Manitoba IBD cohort study: a populationbased study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am. J. Gastroenterol. 103(8), 1989-1997 (2008).
18. Kilroy S, Nolan E, Sarma KM. Quality of life and level of anxiety in youths with inflammatory bowel disease in Ireland. J. Pediatr. Gastroenterol. Nutr. 53(3), 275-279 (2011).
19. Loftus EV Jr, Guérin A, Yu AP et al. Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am. J. Gastroenterol. 106(9), 1670-1677 (2011).
20. Burke P, Meyer V, Kocoshis S et al. Depression and anxiety in pediatric inflammatory bowel disease and cystic fibrosis. J. Am. Acad. Child Adolesc. Psychiatry 28(6), 948-951 (1989).
21. Burke P, Meyer V, Kocoshis S, Orenstein D, Chandra R, Sauer J. Obsessive-compulsive symptoms in childhood inflammatory bowel disease and cystic fibrosis. J. Am. Acad. Child Adolesc. Psychiatry 28(4), 525-527 (1989).
22. Engström I. Mental health and psychological functioning in children and adolescents with inflammatory bowel disease: a comparison with children having other chronic illnesses and with healthy children. J. Child Psychol. Psychiatry. 33(3), 563-582 (1992).
23. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am. J. Gastroenterol. 105(9), 1994-2002 (2010).
24. Arapakis G, Lyketsos CG, Gerolymatos K, Richardson SC, Lyketsos GC. Low dominance and high intropunitiveness in ulcerative colitis and irritable bowel syndrome. Psychother. Psychosom. 46(4), 171-176 (1986).
25. Goldberg D. A psychiatric study of patients with diseases of the small intestine. Gut 11(6), 459-465 (1970).
26. Magni G, Bernasconi G, Mauro P et al. Psychiatric diagnoses in ulcerative colitis. A controlled study. Br. J. Psychiatry 158, 413-415 (1991).
27. Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 28(12), 1600-1604 (1987).
28. Tarter RE, Switala J, Carra J, Edwards KL, Van Thiel DH. Inflammatory bowel disease: psychiatric status of patients before and after disease onset. Int. J. Psychiatry Med. 17(2), 173-181 (1987).
29. Walker EA, Gelfand MD, Gelfand AN, Creed F, Katon WJ. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen. Hosp. Psychiatry 18(4), 220-229 (1996).
30. Mittermaier C, Dejaco C, Waldhoer T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom. Med. 66(1), 79-84 (2004).
31. Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am. J. Gastroenterol. 97(8), 1994-1999 (2002).
32. Creed FH, Ratcliffe J, Fernandes L et al. Depressive, panic and neurasthenic disorders predict poor outcome in severe irritable bowel syndrome unless suitably treated. Br. J. Psychiatry 186, 507-515 (2005).
33. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 97(2), 389-396 (2002).
34. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors. J. Crohns. Colitis (2012).
35. Hyphantis TN, Tomenson B, Bai M, Tsianos E, Mavreas V, Creed F. Psychological distress, somatization, and defense mechanisms associated with quality of life in inflammatory bowel disease patients. Dig. Dis. Sci. 55(3), 724-732 (2010).
36. Raja SN, Williams S, McGee R. Multidimensional health locus of control beliefs and psychological health for a sample of mothers. Soc. Sci. Med. 39(2), 213-220 (1994).
37. Ondersma SJ, Lumley MA, Corlis ME, Tojek TM, Tolia V. Adolescents with inflammatory bowel disease: the roles of negative affectivity and hostility in subjective versus objective health. J. Pediatr. Psychol. 22(5), 723-738 (1997).
38. Bond M. An empirical study of defense styles: the defense style questionnaire. In: Ego Mechanisms of Defense: a Guide for Clinicians and Researchers. Vaillant GE (Ed.). American Psychiatric Press, Washington, DC, USA (1992).
39. Hyphantis TN, Triantafillidis JK, Pappa S et al. Defense mechanisms in inflammatory bowel disease. J. Gastroenterol. 40(1), 24-30 (2005).
40. Leibig T, Wilke E, Feiereis H. Personality structure of patients with ulcerative colitis and Crohn disease, a psychological test study in disease remission. Z. Psychosom. Med. Psychoanal. 31(4), 380-392 (1985).
41. Tocchi A, Lepre L, Liotta G et al. Familial and psychological risk factors of ulcerative colitis. Ital. J. Gastroenterol. Hepatol. 29(5), 395-398 (1997).
42. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand. J. Gastroenterol. 32(10), 1013-1021 (1997).
43. Boye B, Jahnsen J, Mokleby K et al. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease? Inflamm. Bowel Dis. 14(5), 680-686 (2008).
44. Ringel Y, Drossman DA. Psychosocial aspects of Crohn's disease. Surg. Clin. North Am. 81(1), 231-252 (2001).
45. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm. Bowel Dis. 13(2), 225-234 (2007).
46. Goodhand JR, Wahed M, Rampton DS. Management of stress in inflammatory bowel disease: a therapeutic option? Expert Rev. Gastroenterol. Hepatol. 3(6), 661-679 (2009).
47. Bitton A, Sewitch MJ, Peppercorn MA et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 98(10), 2203-2208 (2003).
48. Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 31(2), 179-183 (1990).
49. Duffy LC, Zielezny MA, Marshall JR et al. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav. Med. 17(3), 101-110 (1991).
50. Levenstein S, Prantera C, Varvo V et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 95(5), 1213-1220 (2000).
51. Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig. Dis. Sci. 49(3), 492-497 (2004).
52. Mittermaier C, Dejaco C, Waldhoer T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom. Med. 66(1), 79-84 (2004).
53. Persoons P, Vermeire S, Demyttenaere K et al. The impact of major depressive disorder on the short-and long-term outcome of Crohn's disease treatment with infliximab. Aliment. Pharmacol. Ther. 22(2), 101-110 (2005).
54. Vidal A, Gómez-Gil E, Sans M et al. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am. J. Gastroenterol. 101(4), 775-781 (2006).
55. Bitton A, Dobkin PL, Edwardes MD et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 57(10), 1386-1392 (2008).
56. Deter HC, von Wietersheim J, Jantschek G, Burgdorf F, Blum B, Keller W; German Study Group on Psychosocial Intervention in Crohn's Disease. High-utilizing Crohn's disease patients under psychosomatic therapy. Biopsychosoc. Med. 2, 18 (2008).
57. Levenstein S, Prantera C, Varvo V et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am. J. Gastroenterol. 89(8), 1219-1225 (1994).
58. Maunder RG, Greenberg GR, Hunter JJ, Lancee WJ, Steinhart AH, Silverberg MS. Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress. Am. J. Gastroenterol. 101(11), 2546-2551 (2006).
59. von Wietersheim J, Köhler T, Feiereis H. Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. Psychother. Psychosom. 58(2), 103-112 (1992).
60. Nahon S, Lahmek P, Saas C et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm. Bowel Dis. 17(6), 1270-1276 (2011).
61. Lerebours E, Gower-Rousseau C, Merle V et al. Stressful life events as a risk factor for inflammatory bowel disease onset: a population-based case-control study. Am. J. Gastroenterol. 102(1), 122-131 (2007).
62. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm. Bowel Dis. 12(8), 697-707 (2006).
63. Triantafillidis JK, Hyphantis T, Cheracakis P, Antoniou A, Sklavaina M. Suicide as an outcome in patients with inflammatory bowel disease. Am. J. Gastroenterol. 97(4), 1066-1068 (2002).
64. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm. Bowel Dis. 15(7), 1105-1118 (2009).
65. Cámara RJ, Ziegler R, Begré S, Schoepfer AM, von Känel R; Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion 80(2), 129-139 (2009).
66. Bernstein CN, Walker JR, Graff LA. On studying the connection between stress and IBD. Am. J. Gastroenterol. 101(4), 782-785 (2006).
67. Rampton D. Does stress influence inflammatory bowel disease? The clinical data. Dig. Dis. 27(Suppl. 1), 76-79 (2009).
68. Santos J, Alonso C, Vicario M, Ramos L, Lobo B, Malagelada JR. Neuropharmacology of stress-induced mucosal inflammation: implications for inflammatory bowel disease and irritable bowel syndrome. Curr. Mol. Med. 8(4), 258-273 (2008).
69. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr. Mol. Med. 8(4), 274-281 (2008).
70. Mackner LM, Clough-Paabo E, Pajer K, Lourie A, Crandall WV. Psychoneuroimmunologic factors in inflammatory bowel disease. Inflamm. Bowel Dis. 17(3), 849-857 (2011).
71. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J. Physiol. Pharmacol. 62(6), 591-599 (2011).
72. Gareau MG, Silva MA, Perdue MH. Pathophysiological mechanisms of stress-induced intestinal damage. Curr. Mol. Med. 8(4), 274-281 (2008).
73. Caso JR, Leza JC, Menchén L. The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. Curr. Mol. Med. 8(4), 299-312 (2008).
74. Snoek SA, Verstege MI, Boeckxstaens GE, van den Wijngaard RM, de Jonge WJ. The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease. Expert Rev. Gastroenterol. Hepatol. 4(5), 637-651 (2010).
75. Taché Y, Bernstein CN. Evidence for the role of the brain-gut axis in inflammatory bowel disease: depression as cause and effect? Gastroenterology 136(7), 2058-2061 (2009).
76. Larauche M, Kiank C, Tache Y. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J. Physiol. Pharmacol. 60(Suppl. 7), 33-46 (2009).
77. Taché Y. Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology? Gut 53(7), 919-921 (2004).
78. Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 131(2), 410-419 (2006).
79. Kuroki T, Ohta A, Sherriff-Tadano R et al. Imbalance in the stress-adaptation system in patients with inflammatory bowel disease. Biol. Res. Nurs. 13(4), 391-398 (2011).
80. Matsunaga H, Hokari R, Ueda T et al. Physiological stress exacerbates murine colitis by enhancing proinflammatory cytokine expression that is dependent on IL-18. Am. J. Physiol. Gastrointest. Liver Physiol. 301(3), G555-G564 (2011).
81. Wahed M, Corser M, Goodhand JR, Rampton DS. Does psychological counseling alter the natural history of inflammatory bowel disease? Inflamm. Bowel Dis. 16(4), 664-669 (2010).
82. von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm. Bowel Dis. 12(12), 1175-1184 (2006).
83. Deter HC, Keller W, von Wietersheim J, Jantschek G, Duchmann R, Zeitz M; German Study Group on Psychosocial Intervention in Crohn's Disease. Psychological treatment may reduce the need for healthcare in patients with Crohn's disease. Inflamm. Bowel Dis. 13(6), 745-752 (2007).
84. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clin. Pract. Epidemiol. Ment. Health 2, 24 (2006).
85. Boye B, Lundin KE, Jantschek G et al. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial. Inflamm. Bowel Dis. 17(9), 1863-1873 (2011).
86. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr. Mol. Med. 8(4), 247-252 (2008).
87. Goodhand J, Rampton D. Psychological stress and coping in IBD. Gut 57(10), 1345-1347 (2008).
88. Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst. Rev. 2, CD006913 (2011).
89. Szigethy E, Whitton SW, Levy-Warren A, DeMaso DR, Weisz J, Beardslee WR. Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. J. Am. Acad. Child Adolesc. Psychiatry 43(12), 1469-1477 (2004).
90. Szigethy E, Kenney E, Carpenter J et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J. Am. Acad. Child Adolesc. Psychiatry 46(10), 1290-1298 (2007).
91. Keefer L, Doerfler B, Artz C. Optimizing management of Crohn's disease within a project management framework: results of a pilot study. Inflamm. Bowel Dis. 18(2), 254-260 (2012).
92. Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am. J. Gastroenterol. 103(6), 1460-1469 (2008).
93. Keefer L, Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. Int. J. Clin. Exp. Hypn. 55(4), 457-466 (2007).
94. Keefer L, Kiebles JL, Martinovich Z, Cohen E, Van Denburg A, Barrett TA. Behavioral interventions may prolong remission in patients with inflammatory bowel disease. Behav. Res. Ther. 49(3), 145-150 (2011).
95. Keefer L, Kiebles JL, Kwiatek MA et al. The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial. Biol. Res. Nurs. 14(1), 71-77 (2012).
96. Taft TH, Keefer L, Leonhard C, Nealon-Woods M. Impact of perceived stigma on inflammatory bowel disease patient outcomes. Inflamm. Bowel Dis. 15(8), 1224-1232 (2009).
97. Keefer L, Kiebles JL, Taft TH. The role of self-efficacy in inflammatory bowel disease management: preliminary validation of a disease-specific measure. Inflamm. Bowel. Dis. 17, 614-620 (2011).
98. Kiebles JL, Doerfler B, Keefer L. Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm. Bowel Dis. 16(10), 1685-1695 (2010).
99. Levy RL, Langer SL, Whitehead WE. Social learning contributions to the etiology and treatment of functional abdominal pain and inflammatory bowel disease in children and adults. World J. Gastroenterol. 13(17), 2397-2403 (2007).
100. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68(12), 1833-1838 (2009).
101. Mikocka-Walus AA, Gordon AL, Stewart BJ, Andrews JM. The role of antidepressants in the management of inflammatory bowel disease (IBD): a short report on a clinical case-note audit. J. Psychosom. Res. 72(2), 165-167 (2012).
102. Mikocka-Walus AA, Gordon AL, Stewart BJ, Andrews JM. A magic pill? A qualitative analysis of patients' views on the role of antidepressant therapy in inflammatory bowel disease (IBD). BMC Gastroenterol. 12, 93 (2012).
103. Esposito G, Filippis DD, Cirillo C et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phytother. Res. doi:10.1002/ptr.4781 (2012) (Epub ahead of print).
104. Daneshmand A, Mohammadi H, Rahimian R et al. Chronic lithium administration ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats; potential role for adenosine triphosphate sensitive potassium channels. J. Gastroenterol. Hepatol. 26(7), 1174-1181 (2011).
105. Goodhand JR, Greig FI, Koodun Y et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm. Bowel Dis. 18(7), 1232-1239 (2011).
106. Tang Y, Preuss F, Turek FW, Jakate S, Keshavarzian A. Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. Sleep Med. 10(6), 597-603 (2009).
107. Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A. An initial report of sleep disturbance in inactive inflammatory bowel disease. J. Clin. Sleep Med. 2(4), 409-416 (2006).
108. Ranjbaran Z, Keefer L, Farhadi A, Stepanski E, Sedghi S, Keshavarzian A. Impact of sleep disturbances in inflammatory bowel disease. J. Gastroenterol. Hepatol. 22(11), 1748-1753 (2007).
109. Swanson GR, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? Expert Rev. Clin. Immunol. 7(1), 29-36 (2011).
110. Singh S, Blanchard A, Walker JR, Graff LA, Miller N, Bernstein CN. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 9(9), 769-775 (2011).
111. Makharia GK. Understanding and treating abdominal pain and spasms in organic gastrointestinal diseases: inflammatory bowel disease and biliary diseases. J. Clin. Gastroenterol. 45(Suppl.), S89-S93 (2011).
112. Long MD, Drossman DA. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functionalorganic dichotomy. Am. J. Gastroenterol. 105(8), 1796-1798 (2010).
113. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm. Bowel Dis. 15(5), 778-788 (2009).
114. Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm. Bowel Dis. 18(12), 2301-2309 (2012).